# Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

> **NCT03137264** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 44 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Other

## Key facts

- **NCT ID:** NCT03137264
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-24
- **Primary completion:** 2018-11-10
- **Final completion:** 2018-11-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137264, "Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03137264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*